Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619483 | 0.86 | OPRD1 (0.64) | OPRD1LTA4HACHE | |
| SCHEMBL26619426 | 0.84 | OPRD1 (0.57) | OPRD1 | |
| SCHEMBL27010118 | 0.82 | OPRD1 (0.58) | OPRD1 | |
| SCHEMBL26619347 | 0.81 | OPRD1 (0.62) | OPRD1 | |
| SCHEMBL1189890 | 0.81 | OPRD1 (0.62) | OPRD1 | |
| SCHEMBL27010114 | 0.79 | L3MBTL1 (0.45) | OPRD1 | |
| SCHEMBL24315728 | 0.79 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL27010107 | 0.79 | OPRD1 (0.58) | OPRD1 | |
| Acetic Acid SCHEMBL7448428 | 0.78 | OPRD1 (0.59) | OPRD1 | |
| SCHEMBL24317918 | 0.77 | OPRD1 (0.61) | OPRD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | OPRD1 3512/4885LTA4H 1684/4885ACHE 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.